Dell Children's Medical Group
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Levy, Moise
NCT04917874: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Completed
3
47
US
Open Label Topical Beremagene Geperpavec (B-VEC)
Krystal Biotech, Inc.
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
07/23
07/23
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Not yet recruiting
2
86
US
ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel
National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc.
Atopic Dermatitis
03/26
04/26
Qubty, William
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
03/26
03/26

Download Options